F
Freespira
Freespira is the only FDA-cleared digital therapeutic proven to significantly reduce or eliminate anxiety/panic attacks and PTSD symptoms by training users to normalize respiratory irregularities
About Freespira
Freespira is a digital therapeutics company that offers a non-invasive, drug-free, and FDA-cleared treatment for panic attacks, panic disorder, and post-traumatic stress disorder (PTSD) symptoms. The company primarily serves individuals experiencing these conditions, with a business model centered on providing a four-week at-home treatment program. This program utilizes a proprietary sensor and a connected mobile app to guide users through twice-daily sessions of personalized breathing exercises. The core of Freespira's technology is to normalize the user's breathing patterns by regulating their exhaled carbon dioxide levels and respiratory rate, which are often dysregulated in individuals with panic and PTSD. By training users to stabilize their breathing, the treatment aims to reduce or eliminate panic attacks and other related symptoms within 28 days. The company generates revenue by selling this treatment program, which is authorized and monitored by healthcare professionals. Freespira operates in the mental and behavioral health market, offering a digital alternative to traditional therapies and medications.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Kirkland, United States
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 60.2/100
- Industry
- Health
- Sub-industry
- Medical Devices, Health Platform
- Sector
- Health Tech & Medtech, Mental Health, Chronic Disease, Non-Invasive medical devices and treatments, Spinout, Sustainable Development Goals, Digital Therapeutics, Tech for Biotech and Pharma, Tech for Patients
- Technology
- Deep Tech
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Apr 2024 | $23M | $90M | Undisclosed | ↗ |
| LATE VC✓Equity / VC | Dec 2020 | $10M | $40M | Lightspeed Venture Partners · Medvest Capital · Russell Siegelman · Aphelion Capital | — |
Growth signals
Latest recorded traffic for Freespira is 6.1K monthly website visits, up 45.2% over the last three months. Freespira's team declined 30% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series B and later5 investors entered at this stage
Farzad (Zod) Nazem
Lightspeed Venture Partners- MCMedvest Capital
Russell Siegelman- ACAphelion Capital
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Freespira on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Freespira’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.